You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
“Drs. Butterfield, Kaufman and Marincola on behalf of the SITC have created a comprehensive must-have resource covering the basic and translational science behind approved and investigational immune therapies, and disease-by-disease clinical application of the therapies, written by leaders in the field. The textbook will be highly valuable reading for those just entering the field and for experienced scientists and clinicians looking to expand their knowledge base.” —Mario Sznol, MD, Professor of Medicine (Medical Oncology), Yale School of Medicine, New Haven, Connecticut “Given the important and exciting advances in cancer immunotherapy, it is not surprising that there is no dearth ...
This book brings together the world’s leading authorities on tumor immunology. This book describes the basic immunology principles that form the foundation of understanding how the immune system recognizes and rejects tumor cells. The role of the innate and adaptive immune responses is discussed and the implications of these responses for the design of clinical strategies to combat cancer are illustrated.
None
None
Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.
Using viruses to treat cancer is an established concept, and many viruses have shown promising anti-tumor efficacies. Oncolytic viruses are safe and well-characterized pathogens with a stable genome. The outstanding clinical results for oncolytic virotherapy deserve serious attention and consideration to make it a treatment option alongside classical cancer therapeutics. Virotherapy uses replication-competent oncolytic viruses to replicate and destroy cancer cells selectively. The transformed nature of cancer cells offers a permissive environment for some viruses’ replication and to complement viral mutations. The in situ amplification and spread within the tumor mass is the key benefit of such replication-competent viruses. Oncolytic virotherapy is divided into two main groups, according to tumor specificity: naturally oncolytic viruses to replicate in human cancer cells; and gene-modified viruses engineered to accomplish selective oncolysis.